QRVO
38
5
NOV
48
3
DE
45
5
SCHW
49
4
PCAR
53
5
SJM
41
8
LNC
50
11
MET
54
3
CMS
64
-3
XEL
62
-3
AVGO
49
9
LB
45
4
UAL
54
-2
BAC
47
8
URI
63
4
LLY
50
3
KMI
57
-2
JCI
54
2
NTRS
54
7
JNJ
47
-4
QRVO
38
5
NOV
48
3
DE
45
5
SCHW
49
4
PCAR
53
5
SJM
41
8
LNC
50
11
MET
54
3
CMS
64
-3
XEL
62
-3
AVGO
49
9
LB
45
4
UAL
54
-2
BAC
47
8
URI
63
4
LLY
50
3
KMI
57
-2
JCI
54
2
NTRS
54
7
JNJ
47
-4
Financhill
Back

Emergent BioSolutions 10K Form

Sell
24

EBS
Emergent BioSolutions

Last Price:
6.99
Seasonality Move:
-1.05%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-02 10Q EBS/Emergent BioSolutions Quarterly
2023-12-11 10Q EBS/Emergent BioSolutions Quarterly
2023-08-09 10Q EBS/Emergent BioSolutions Quarterly
2023-05-10 10Q EBS/Emergent BioSolutions Quarterly
2022-11-09 10Q EBS/Emergent BioSolutions Quarterly
2022-08-02 10Q EBS/Emergent BioSolutions Quarterly

Receive EBS News And Ratings

See the #1 stock for the next 7 days that we like better than EBS

EBS Financial Statistics

Sales & Book Value

Annual Sales: $1.02B
Cash Flow: $42.9M
Price / Cash Flow: 9.7
Annual Sales: $7.30
Price / Book: 0.96

Profitability

EPS (TTM): -11.24000
Net Income (TTM): $-587M
Gross Margin: $317.6M
Return on Equity: -87.53%
Return on Assets: -31.86%

Emergent BioSolutions Earnings Forecast

Key Emergent BioSolutions Financial Ratios

  • The Gross Profit Margin over the past 22 years for EBS is 31.05%.
  • The Selling, General & Administrative Expenses for EBS have been equal to 36.01% of Gross Profit Margin.
  • The Research & Development expenses have been 10.89% of Revenue.
  • The Interest Expense is -11.56% of Operating Income.
  • The Net Earning history of EBS is -74.34% of Total Revenues.
  • Per Share Earnings over the last 23 years have been positive in 12 years.

Emergent BioSolutions Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biotechnology
Sector: Health Care
Current Symbol: EBS
CUSIP: 29089Q
Website: emergentbiosolutions.com

Debt

Debt-to-Equity Ratio: 2.23
Current Ratio: 1.06
Quick Ratio: 0.43

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

EBS Technical Analysis vs Fundamental Analysis

Sell
24
Emergent BioSolutions (EBS) is a Sell

Is Emergent BioSolutions a Buy or a Sell?